The €4.5 million ($4.2 million) effort is led by researchers from Sweden's Karolinska Institute and aims to deliver lateral flow tests and point-of-care devices.
The clinical chemistry test is intended to help diagnose heart failure using the N-terminal pro b-type natriuretic peptide biomarker.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback